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Abstract 
Asthma is a chronic inflammatory immune disorder of the airways affecting one in ten children in westernized 
countries. The geographical disparity combined with a generational rise in prevalence, emphasizes that changing 
environmental exposures play a significant role in the etiology of this disease. The microflora hypothesis suggests 
that early life exposures are disrupting the composition of the microbiota and consequently, promoting immune 
dysregulation in the form of hypersensitivity disorders. Animal model research supports a role of the microbiota in 
asthma and atopic disease development. Further, these model systems have identified an early life critical window, 
during which gut microbial dysbiosis is most influential in promoting hypersensitivity disorders. Until recently this 
critical window had not been characterized in humans, but now studies suggest that the ideal time to use microbes 
as preventative treatments or diagnostics for asthma in humans is within the first 100 days of life. This review outlines 
the major mouse-model and human studies leading to characterization of the early life critical window, emphasiz-
ing studies analyzing the intestinal and airway microbiotas in asthma and atopic disease. This research has promising 
future implications regarding childhood immune health, as ultimately it may be possible to therapeutically administer 
specific microbes in early life to prevent the development of asthma in children.
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Background
Recent evidence supports a role of the intestinal microbi-
ome in the development of childhood asthma and atopic 
disease. Animal model studies have made significant 
advancements in the quest to understand the gut-lung 
axis; identifying large-scale shifts in gut microbial com-
positions in asthma and allergy-induced mice and manip-
ulating the intestinal microbiome with antibiotics, which 
enhanced the severity of these diseases [1–3]. However, 
with the advancement of DNA and RNA sequencing 
technologies and the establishment of large longitudi-
nal human birth cohorts, it is becoming clearer that gut 
microbial dysbiosis in human atopic diseases is charac-
terized not by global changes to the composition of the 
intestinal microbiota, but by taxa-specific shifts in abun-
dance at the family, genus, and even species’ levels [4–6]. 
Perhaps unsurprisingly, these taxa-specific changes are 
most prominent within the first 100  days of life, during 
which the human immune system is most plastic in its 
development [4–6]. Given these scientific developments, 
this review aims to provide an overview of the recent 
advances in human microbiome research in asthma and 
atopic disease.
The global burden of asthma and atopic disease
Allergic asthma is an immunoglobulin E (IgE)-mediated 
chronic inflammatory disease of the airways [7]. Other 
manifestations of IgE-mediated or “atopic” diseases 
include: atopic dermatitis (also referred to as eczema), 
allergic rhinitis, and food allergy [8]. These diseases typi-
cally manifest in early childhood and can be chronic life-
long burdens for many people. However asthma is often 
viewed as the most burdensome atopic disorder, due 
to the prevalence (235 million people worldwide) and 
associated mortality (an estimated nine asthma-related 
deaths per day in the United States) [9, 10]. Asthma has 
become the most prevalent childhood disease in recent 
decades, affecting approximately one in ten children 
Open Access
Allergy, Asthma & Clinical Immunology
*Correspondence:  sturvey@cw.bc.ca 
4 Department of Pediatrics, BC Children’s Hospital, 950 West 28th Avenue, 
Vancouver, BC V5Z 4H4, Canada
Full list of author information is available at the end of the article
Page 2 of 9Stiemsma and Turvey  Allergy Asthma Clin Immunol  (2017) 13:3 
worldwide [8]. Aside from the obvious danger associated 
with asthma, this disease is very disruptive to a normal 
daily lifestyle for children, and is the leading cause of 
emergency room visits and absenteeism from school [11].
Some of the most striking data related to asthma 
prevalence comes from the United States, where it was 
reported from 1999 to 2009, that the proportion of peo-
ple diagnosed with asthma increased by 15% [10]. In 
other Westernized countries (e.g. Canada, Australia, and 
the UK) the prevalence of this disease was reported to be 
even higher (up to 30% in some countries), while many 
countries in Eastern Europe and Asia report a much 
lower prevalence of this disease (~5%) [8, 12, 13]. This 
rapid increase in prevalence of asthma (and other atopic 
diseases) as well as the apparent geographical disparity 
suggests an etiology that is more complex than popula-
tion genetic variation.
‘The post‑industrial epidemic’
The underlying cause of asthma is a complex product of 
genetic and environmental factors resulting in significant 
heterogeneity of the disease. Parental history of asthma 
increases the likelihood of developing this disease, how-
ever assessment of this factor alone is not enough to 
confirm a person’s risk of asthma development [14–16]. 
There is also evidence of a strong link between sex and 
increased risk of asthma development in children, as boys 
are more likely to develop childhood asthma than girls 
[17, 18]. Further, genome-wide-association-studies have 
identified candidate genes that play a role in asthma sus-
ceptibility (ORMDL3 and SMAD3) [19]. Thus it is clear 
that human genetics contribute to asthma pathogenesis, 
however the rapid rise in asthma prevalence suggests 
changing environmental factors are biasing the develop-
ing human immune system toward these hypersensitivity 
diseases [20].
In addition to the within-generation rise in the preva-
lence of asthma, there is also an inverse relationship 
between the incidence of infectious diseases and hyper-
sensitivity diseases, where a high incidence of infectious 
diseases appears to protect against allergic and autoim-
mune diseases [21]. Further, the geographical disparity 
of asthma and atopic diseases is shifting, as developing 
countries become industrialized and their living condi-
tions become more like the Western world [22]. Thus it 
appears that there may be a link between the develop-
ment of hypersensitivity diseases and the urbanization 
or modernization of society [23]. Many urban environ-
ments have similar characteristics (lower air quality, 
higher population density, lower economic status) that 
predispose populations to asthma; and similar to the 
geographical disparity of this disease, rural areas with 
comparable environments do report greater incidences 
of hypersensitivity diseases [24, 25]. There is also the 
possibility that urbanization does not support optimal 
immune development due to a decrease in exposure to 
environmental microbes as humans shift from an out-
door lifestyle to a more indoor lifestyle that is character-
istic of urban societies [26].
This concept of decreased microbial exposure in 
modern or more urban societies has become a boom-
ing research area in the etiology of immune dysregula-
tion. One particular arm of asthma etiology in particular, 
focuses on factors associated with improved health and 
hygiene; for example, increased antibiotic exposure, and 
household size [23, 27–35]. In particular, David Strachan 
extensively studied the relationship between household 
size and atopic disease in the late 1980s, and his initial 
findings led him to propose the hygiene hypothesis of 
allergic disease in 1989 [36]. This hypothesis sets the 
stage for the current analyses assessing the role of micro-
bial exposure in the development of asthma and other 
hypersensitivity disorders.
External and internal microbes as protectors 
against asthma
The hygiene hypothesis
The hygiene hypothesis proposes that a lack of early 
life exposure to microbes alters early life immune sys-
tem priming and, consequently, increases susceptibil-
ity to atopic diseases [20]. Strachan theorized that older 
siblings promote increased exposure to environmen-
tal microbes through inevitable unhygienic contact, 
which results in decreased likelihood of atopic disease 
development in younger siblings [36]. He supported his 
hypothesis by showing that household size was inversely 
correlated with the development of hay fever (i.e. aller-
gic rhinitis) in a cohort of 11,765 children [37]. Since 
Strachan’s original proposal, the hygiene hypothesis has 
expanded to include additional environmental factors 
(such as mode of birth, antibiotic exposure, household 
pets, etc.), which also alter the microbial exposure of 
infants [33–35]. Further, with substantial improvements 
in genetic sequencing technology, the role of indigenous 
microbes has also been added to the mix.
The microflora hypothesis
The microflora hypothesis extends Strachan’s hygiene 
hypothesis by emphasizing the role of microbes resid-
ing in and on the human body (collectively known as 
the human microbiota) [38]. Originally, these microbes 
were considered to be commensal, having little effect on 
human physiology [38]. However they have since been 
implicated extensively in human health and develop-
ment, and it is clear that there is a microbial-immune 
cell interface, in which cross-talk between microbes and 
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immune cells aids in the development of immune toler-
ance [39–42]. Notably, the focus of this hypothesis is the 
gastrointestinal tract, one of the most populated zones 
of the human body [38]. It proposes that perturbations 
to the colonization and composition of the intestinal 
microbiota (dysbiosis), disrupts this natural microbe-
immune cell interface, biasing the developing infant 
immune system toward a hyper-sensitive (allergic) state 
[38, 43]. In support of the microflora hypothesis, a recent 
study found that uncontacted Amerindians (indigenous 
peoples of the Americas) exhibited higher levels of bac-
terial and functional diversity in their skin and fecal 
microbiota than any other human population previously 
reported, suggesting that modern societal practices (per-
turbations) have strong implications in the development 
of the microbiota [44]. Regarding the role of the intesti-
nal microbiome in asthma, the gut-lung axis attempts 
to explain the mechanisms guiding gut microbe-lung 
immune cell cross talk.
The gut‑lung axis
Innate immunity microbial crosstalk
The gut-lung axis attempts to mechanistically define 
how microbes in the gut might influence immune func-
tion in the lung [45]. One potential connection is through 
interactions of the gut microbiota with pattern recogni-
tion receptors of the innate immune system [46]. It is 
well established that pathogen-associated molecular pat-
terns (PAMPs) such as lipopolysaccharide (LPS), CpG, 
and peptidoglycan can stimulate Toll-like receptor (TLR) 
signaling, which confers downstream activation of many 
genes that regulate inflammation and innate immune 
responses [47]. Similar to the antigen-recognition and 
IgE-mediated hypersensitivity pathways, dendritic cells 
(DCs) are also the intermediaries of gut microbiota-
immune cell cross talk, as they regularly sample gut 
microbes in the intestinal lumen or lymphoid tissues [46]. 
DC sensing of gut microbiota PAMPs promotes immune 
tolerance in the intestine, but also results in phenotypic 
changes to DCs and migration to the mesenteric lymph 
node (MLN) to promote T cell priming [48]. In the 
MLN, T cells also acquire homing molecules (e.g. CCR4, 
CCR6), which initiate migration to other parts of the 
body, including the respiratory mucosa [49].
Thus it is possible that interactions with specific gut 
microbes, via their corresponding PAMPs, could result 
in varying phenotypic changes in DCs, with downstream 
effects on lymphocyte priming/homing and ultimately, 
shifts in anti-inflammatory responses in the airways [49]. 
In a house dust mite (HDM) model of allergic inflamma-
tion, chronic intranasal exposure to endotoxin (bacterial 
LPS) has been shown to protect mice from HDM-induced 
asthma [50]. The proposed mechanism of this protection 
is through A20 (ubiquitin modifying enzyme)-mediated 
inhibition of HDM-induced recruitment of conventional 
DCs to the lungs and mediastinal lymph nodes [50]. Fur-
ther, prior 2-week treatment of mice with LPS suppressed 
proliferation and differentiation of adoptively transferred 
CD4+  HDM-specific 1-DER T cells in the mediastinal 
lymph nodes into IL-5 and IL-13—secreting T-helper 
(Th)-2 cells, highlighting the T cell priming effects of 
these DCs [50]. Though this is not a gut microbiota medi-
ated pathway, it does highlight the ability of bacterial 
PAMPs (specifically LPS) to alter DC recruitment to the 
lungs and protect mice against asthma symptoms.
Role of microbial‑derived metabolites—short chain fatty 
acids
Another area of gut-lung axis research involves micro-
bial-derived metabolites, such as short chain fatty acids 
(SCFAs). SCFAs are direct by-products of bacterial fer-
mentation of carbohydrates and are key energy sources 
for many host tissues and gut bacterial species [51]. There 
are three major SCFAs, acetate, propionate, and butyrate, 
which are present in a molar ratio of 60:20:20, respectively 
[51]. These metabolites are known to modify gene expres-
sion through inhibition of histone deacetylases (HDACs), 
cytokine and chemokine production, and cell differen-
tiation, proliferation, and apoptosis [52]. With regard 
to immune tolerance and inflammatory mechanisms, 
butyrate and propionate induce extrathymic T-regulatory 
(T-reg) generation through direct interactions with T 
cells and indirect interactions through DCs, potentially 
through the inhibition of HDACs [53]. Clostridial species 
are prominent SCFA producers, and butyrate produc-
tion by these particular bacteria was associated with the 
generation of peripheral T-reg cells in the colon [54]. In a 
HDM-mouse model of experimental asthma, both acetate 
and propionate were capable of reducing cellular infiltra-
tion into the airways after HDM exposure [55]. Systemic 
propionate treatment modified bone marrow hemat-
opoiesis and enhanced the generation of DC and mac-
rophage precursors and subsequent recruitment of DCs 
less effective in promoting Th-2 cell polarization in the 
lungs [55]. In a later study using the same asthma mouse 
model, maternal intake of acetate was shown to reduce 
allergic airways disease in the adult offspring of mice [56]. 
Notably, both these studies initially assessed the role of a 
high fiber diet on the production of SCFAs and coloniza-
tion of intestinal bacteria—highlighting the influence of 
diet, mediated by gut microbial changes, on the devel-
opment of the immune system [55, 56]. The latter study, 
however, emphasizes intrauterine effects on the infant 
immune system, mediated by maternal diet, suggesting 
the need to consider prenatal prevention strategies using 
these gut microbial metabolites [56].
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Microbial influences on epigenetics
It is also possible that the intestinal microbiota is linked 
to lung immunity through microbe-mediated epigenetic 
modification. Distinct whole blood DNA methylation 
patterns were associated with two major bacterial phyla, 
either Firmicutes or Bacteroidetes and pathway analy-
sis revealed differential methylation (associated with a 
high or low Firmicute/Bacteroidetes ratio) among genes 
enriched in functional networks such as cardiovascu-
lar disease, inflammatory responses, obesity, and lipid 
metabolism [57]. Further, production of bacterial methyl 
groups, cofactors (e.g. folate), and enzymes (e.g. methyl-
transferases) can both directly and indirectly affect host 
DNA methylation, and consequently may bias cell differ-
entiation toward or against an immune profile that con-
fers tolerance [58, 59]. There is also evidence that early 
life farm microbial exposures may influence the meth-
ylation of genes related to asthma and allergies [60, 61]. 
Lastly, reinforcing the age-sensitive role of the intestinal 
microbiota in hypersensitivity diseases, the presence of a 
conventional gut microbiota in previously germ-free (GF) 
neonatal (but not adult) mice decreased hypermethyla-
tion of CXCL16, which in turn decreased accumulation 
of invariant natural killer T (iNKT) cells (prominent in 
the pathogenesis of asthma) in the colon [41]. Thus ulti-
mately, there is much more to learn regarding the mech-
anisms of the gut-lung axis in asthma and other lung 
disorders. Current research in asthma and atopic dis-
ease centers around how, mechanistically, the intestinal 
microbiota is linked to these disorders and whether early 
life changes to the intestinal microbiome can be thera-
peutically manipulated to promote immune tolerance.
The intestinal microbiota in asthma and atopic 
disease
Mechanistic studies analyzing how the intestinal micro-
biome is involved in asthma and atopic disease are 
typically conducted in mouse models of allergic inflam-
mation. GF mice lacking a microbiota show increased 
allergic responses, including increased lymphocyte and 
eosinophil inflammation in the airways, accompanied 
by increased Th-2 cytokines and elevated IgE produc-
tion [62]. However many animal studies also focus on 
roles of distinct bacterial taxa in atopic disease devel-
opment. In an ovalbumin (OVA)-model of asthma, oral 
supplementation of mice with two types of Lactoba-
cillus showed that protection from allergic responses 
is mediated by specific bacterial species [63]. Supple-
mentation with live Lactobacillus reuteri resulted in 
decreased airway hyper responsiveness, while treat-
ment with Lactobacillus salivarius had no effect on the 
allergic symptoms of the mice [63]. This species-specific 
effect was also shown using three bacterial species, 
Bifidobacterium longum, Bifidobacterium breve and L. 
salivarius [1]. L. salivarius had no effect, and both Bifi-
dobacterium species increased Peyer’s patch and splenic 
Foxp3+ T-reg cells in infant mice [1]. However, only B. 
longum introduced in the perinatal period resulted in 
T-reg cell induction in adult mice and protected against 
allergic airway inflammation in OVA-sensitized mice 
[1]. Notably, the age-sensitive induction of T-regs in 
adult mice by B. longum suggests the presence of an 
early life window in which microbial-driven immune 
changes are most effective.
Antibiotics (which disturb the intestinal microbiota 
composition) have also been shown to increase airway 
inflammation in mouse models of experimental asthma 
[2, 64, 65]. One study showed that combined oral anti-
biotic treatment of mice resulted in increased allergic 
inflammation, characterized by increases in serum IgE 
and circulating basophils [65]. Conventionally raised 
mice showed decreased proliferation of bone-marrow 
resident basophil precursors compared to the antibiotic 
treated mice, suggesting that these shifts in immune cells 
were mediated by alterations to the microbiota [65]. Thus 
collectively, these mouse model studies show that gut 
microbial alterations can result in changes in lung func-
tion, but it is becoming clearer through improved mouse-
models and longitudinal human cohort research, that 
these microbe-mediated changes in immune develop-
ment are most effective in early infancy.
Mouse studies suggest an early life critical window
Age is the main driver of compositional and functional 
differences in the intestinal microbiota [4, 66]. Thus it is 
perhaps unsurprising that many mouse studies assess-
ing the role of the gut microbiota in atopic disease, find 
the results to be time sensitive (Fig.  1a). Cahenzli et  al. 
demonstrate that global shifts in the composition of the 
intestinal microbiota (increased microbial diversity) 
in early life is required to regulate IgE production and 
decrease disease severity in a mouse-model of antigen-
induced oral anaphylaxis [67]. In OVA- and HDM-mod-
els of allergic airway inflammation, oral infection with 
CagA-positive Helicobacter pylori resulted in protection 
against OVA and HDM-induced airway hyper respon-
siveness [68]. However, this bacterium-mediated protec-
tion against asthma was more apparent in mice infected 
neonatally compared to mice infected as adults [68]. As 
noted in the previous section (microbial influences on 
epigenetics), neonatal (but not adult-life) exposure to a 
conventional microbiota in GF OVA-challenged mice 
abrogated iNKT cells in the lungs and reduced serum 
IgE, proinflammatory cytokine levels, and eosinophilia 
in the bronchoalveolar lavage fluid, protecting mice from 
developing allergic asthma symptoms [41].
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Russell et al. demonstrate the effects of early life anti-
biotic exposure in mice [2, 3]. This group showed that 
perinatal (in utero and up to 21  days after birth until 
weaning) versus strictly prenatal (in utero) vancomycin 
treatment of OVA-challenged mice exacerbates asthma-
related immune responses [2]. Further, perinatal treat-
ment of mice with another antibiotic, streptomycin, 
exaggerated lung inflammation in a Th-1/Th-17-driven 
model of hypersensitivity pneumonitis [3]. Notably, each 
antibiotic promoted expansion of specific bacterial phyla; 
streptomycin promoted expansion of Bacteroidetes, 
while vancomycin promoted expansion of Firmicutes [3]. 
This highlights both the selective effects of antibiotics on 
gut microbial taxa and the ability of an antibiotic-altered 
microbiota to differentially enhance disease susceptibil-
ity to specific lung diseases [3, 64]. Notably, all of these 
studies highlight a critical window (from birth to wean-
ing in mice) in which microbial alterations can promote 
or protect against asthma and atopic diseases. However 
until recently, this critical window was not characterized 
in humans.
Longitudinal human studies define the early life 
critical window
Mouse studies have made substantial mechanistic 
strides in microbiome-atopic disease research. In paral-
lel, improvements in DNA sequencing technology over 
the past decade have made analyzing the microbiomes 
of humans much more feasible. With these sequenc-
ing improvements, a similar ‘critical window’ in which 
microbial alterations can be associated with the develop-
ment of asthma and atopic disease is also becoming more 
apparent in humans (Fig. 1b). Using 454-pyrosequencing, 
one study associated changes in gut microbial diversity at 
1-week and 1-month of age with asthma development at 
school age [69].
a
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Fig. 1 Defining the critical window of early life in a mice and b humans
Page 6 of 9Stiemsma and Turvey  Allergy Asthma Clin Immunol  (2017) 13:3 
However more recent studies have identified shifts 
in specific bacterial taxa in early life, rather than 
global compositional changes, that are associated with 
increased risk of asthma later in life. In fact, our group 
identified decreases in the abundances of four bacterial 
genera, Faecalibacterium, Lachnospira, Rothia, and Veil-
lonella (FLVR), in the 3-month fecal microbiota, which 
were associated with atopy and wheezing at 1-year of 
age among 319 infants enrolled in the Canadian Healthy 
Infant Longitudinal Development (CHILD) Study [4]. 
Atopy and wheezing are clinically used to predict asthma 
development in children, and subjects positive for both 
atopy and wheezing were most likely (compared to 
wheeze only, atopy only, and control subjects) to develop 
asthma by 3-years of age—suggesting that these early life 
genera shifts are associated with increased risk of asthma 
development [4]. Further, these four bacterial taxa ame-
liorated asthma in an OVA-challenged mouse model, 
supporting their immune-modulatory roles in protecting 
against asthma development [4].
Since the CHILD Study is a longitudinal cohort, our 
group was able to conduct a follow-up study on this 
same cohort when they reached 4-years of age and could 
be diagnosed with preschool-age asthma [5]. We found 
that Lachnospira remained decreased in the 3-month 
fecal microbiota while one particular bacterial species, 
Clostridium neonatale, was increased in asthmatics at 
this time-point [5]. Demonstrating the diagnostic poten-
tial of these particular microbes, we calculated a ratio 
of Lachnospira to C. neonatale (L/C) and using quartile 
analysis, showed that children with the lowest L/C ratio 
(quartile 1) were 15 times more likely to be diagnosed 
with preschool-age asthma than children in the other L/C 
quartiles [5]. Most interestingly, however, both of these 
studies identified these gut microbial changes in the first 
3 months of life only, highlighting this time frame as the 
early life critical window during which gut microbial dys-
biosis is most influential in promoting asthma and atopic 
disease in humans [4, 5].
Notably however, additional bacterial taxa as well as 
other microbes (e.g. fungi) have been associated with 
asthma and atopic disease development in children [6, 
70]. In fact, a recent study published in Nature Medicine 
was able to distinguish asthmatic and atopic children by 
their neonatal (35  days post birth) intestinal microbi-
ome compositions [6]. Children in the highest risk group 
showed shifts in specific bacterial and fungal taxa, high-
lighting roles of various gut microbes in human immune 
development, which are identifiable even earlier than 
3-months of age [6]. Thus, even now it is becoming more 
evident that; (i) there are likely many other gut microbes 
associated with asthma and atopic disease develop-
ment in humans; and (ii) that the ‘critical window’ for 
identifying these gut microbial shifts in humans could 
be even smaller than 100 days post birth. Further, in an 
effort not to overlook a potentially obvious link between 
the microbiome and airway inflammation, recent stud-
ies have identified associations and mechanistic links 
between airway microbes and asthma and atopic disease 
development.
Role of the airway microbiota
Though the intestinal microbiome is one of the most 
populated regions of the human body, recent research 
supports a role of the airway microbiome in asthma and 
atopic disease pathogenesis. In an OVA-induced mouse 
model of asthma, administration of a common gut patho-
gen, E. coli, to the lung was shown in a TLR4-dependent 
manner to induce γδ-T cells, decrease activation of lung 
DCs, and abrogate Th-2 cytokine production to confer 
protection of mice from allergic airway inflammation 
[71].
In humans, airway microbial dysbiosis has been asso-
ciated with increased risk of asthma [72, 73]. 16S rRNA 
analysis of sputum samples showed higher bacterial 
diversity and increased abundance of Proteobacteria in 
asthmatic adults compared to non-asthmatic adults [73]. 
Another adult study analyzing the bronchial microbiota 
was able to identify differences in microbial composition 
associated with asthma severity [72]. When compared to 
healthy controls, severe asthmatics were enriched in Act-
inobacteria and Klebsiella species [72]. However com-
pared to patients with moderate asthma, patients with 
severe asthma were enriched in many Actinobacterial 
taxa and showed decreased abundances of Proteobacte-
ria [72].
Continuing the early life theme, Gollwitzer et  al. pro-
vide evidence of a 2-week window in which shifts in 
the airway microbiota are associated with decreased 
responsiveness to aeroallergens and the induction of 
Helios− T-regs in a programmed death ligand 1 (PD-L1)-
mediated manner [74]. If PD-L1 is blocked only in the 
first two weeks of life and allergic airway inflammation 
is induced after 4-weeks of age, the exaggerated allergic 
airway inflammation in neonatal mice is maintained to 
adulthood [74]. Further, in a study of 234 human chil-
dren, researchers associated early (7–9 weeks post-birth) 
asymptomatic colonization with Streptococcus in the 
nasopharyngeal (NP) microbiome with chronic wheezing 
at ages 5 and 10 years [75]. Interestingly, they also suggest 
the NP microbiome as a determinate for the spread of 
respiratory infections to the lower airways, which are also 
significant risk factors for asthma development [75]. Thus 
there may be specific early life non-pathogenic airway 
microbes associated with asthma, but it is also possible 
that dysbiosis in the airway microbiota is the mediator 
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between respiratory infections and subsequent develop-
ment of asthma.
Conclusions and future directions
In conclusion, the current literature suggests a role of 
the microbiome in asthma and atopic disease develop-
ment, with particular emphasis on early life dysbiosis. 
Notably, recent studies have identified shifts in specific 
bacterial genera and species, which could ultimately be 
applied as probiotic interventions prior to the develop-
ment of asthma. These probiotic interventions could be 
given directly to the baby in early infancy once all safety 
concerns have been addressed. Another option for colo-
nizing the infant is through maternal exposure to these 
microbes either before or after delivery. Prior to estab-
lishing these probiotic regimens however, shifts in early 
life gut and airway microbes could also be applied as 
microbe-based diagnostics to identify children at the 
highest risk of developing asthma and related allergic 
diseases.
Before any of these preventative or diagnostic tech-
niques can be applied, future research should focus on 
validating the current findings in additional longitudinal 
human cohorts and improving humanized microbiome 
mouse models of airway and lung inflammation to mech-
anistically characterize the microbe-immune cell interac-
tions promoting or protecting against asthma and atopic 
disease. Additionally, targeted-metabolomic and shotgun 
metagenomic sequencing strategies using stool, urine, 
and potentially breast-milk samples in human cohorts 
will better characterize the functional roles of these spe-
cific taxa in infant immune development.
Further, to better elucidate this early life critical win-
dow in humans, additional longitudinal cohorts should 
begin stool sample collection beginning at birth and con-
tinuing up to age 1 year (with at least bi-weekly collection 
points within the first 3-montths of life). Additionally, the 
collection of additional biological samples (namely blood 
and urine) during the first 3-months of life (though this is 
not often feasible) would be ideal to determine whether 
these gut microbial alterations occur prior to immune-
dysregulation or vice versa.
Moreover, although this review focuses on the bacte-
rial microbiome in asthma, there are many other micro-
bial organisms (fungi and other eukarya, and viruses) 
that also play key roles in host physiology and immune 
development [6, 76–79]. Also, with the characterization 
of other microbiomes within the human body (i.e. pla-
cental, blood, breast-milk), it is likely that we will identify 
even more microbial taxa that are associated with airway 
diseases. As discussed in the previous sections, there is 
evidence in mice that asthma is a developmental origin 
disease, mediated by maternal gut microbial alterations 
in utero [56]. Thus it will be important to incorporate 
multi-biome analyses to potentially identify: (i) how chil-
dren are being colonized with specific asthma related 
microbes; and (ii) roles of other microbial taxa in the 
pathogenesis of asthma and atopic disease. Ultimately 
however, this literature review presents research with 
promising future directions, offering an exciting outlook 
for future microbe-based preventative treatments and 
diagnostic strategies for asthma and atopic disease in 
children.
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